Tamburrino Federica, Mazzanti Laura, Gibertoni Dino, Schiavariello Concetta, Perri Annamaria, Orlandini Eleonora, Rossi Cesare, Tartaglia Marco, Lanari Marcello, Scarano Emanuela
Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Alma Mater University of Bologna, Bologna, Italy.
Front Endocrinol (Lausanne). 2025 Jan 17;15:1531545. doi: 10.3389/fendo.2024.1531545. eCollection 2024.
RASopathies, including Noonan syndrome and related disorders, are multisystem conditions caused by mutations in various genes encoding proteins involved in the RAS/MAPK signaling pathway resulting in increased signal flow. They are clinically characterized by failure to thrive, facial dysmorphisms, congenital heart defects, lymphatic malformations, skeletal anomalies, and variable cognitive impairment, with variable prevalence in the different conditions and subtypes. Pubertal development, which affects growth and final height, is often delayed in Noonan syndrome patients, though not universally. This study aimed to evaluate the timing and progression of puberty and its impact on growth and final height in patients with RASopathies.
A retrospective longitudinal study was conducted involving 103 patients with molecularly confirmed RASopathies. A subgroup of 40 patients who had completed pubertal development was analyzed. Anthropometric, hormonal (FSH, LH, estradiol/testosterone), and radiological data were collected.
Among the 40 patients who had completed puberty, 75% had a diagnosis of Noonan syndrome. The median age at pubertal onset was 11.8 years in males and 13.2 years in females. Delayed puberty was observed in 27.8% of patients, with a higher incidence in females. Median final height was significantly lower in those with delayed pubertal onset compared to those with normal development (p < 0.01). No significant differences in final height were observed between patients with growth hormone deficiency treated with growth hormone and those who were untreated.
Delayed pubertal onset negatively impacts final height in patients with RASopathies, with inadequate pubertal catch-up growth being a common outcome. While most patients initiate puberty spontaneously, careful monitoring of growth and pubertal progression is crucial to optimize therapeutic interventions and improve final height outcomes.
RAS病,包括努南综合征及相关疾病,是由参与RAS/丝裂原活化蛋白激酶(MAPK)信号通路的各种蛋白质编码基因突变引起的多系统疾病,导致信号传导增加。其临床特征为生长发育迟缓、面部畸形、先天性心脏缺陷、淋巴管畸形、骨骼异常以及不同程度的认知障碍,在不同疾病和亚型中的患病率各不相同。青春期发育会影响生长和最终身高,努南综合征患者的青春期发育通常会延迟,但并非普遍现象。本研究旨在评估RAS病患者青春期的启动时间和进展情况及其对生长和最终身高的影响。
进行了一项回顾性纵向研究,纳入103例经分子确诊的RAS病患者。对40例已完成青春期发育的患者亚组进行了分析。收集了人体测量、激素(促卵泡生成素、促黄体生成素、雌二醇/睾酮)和放射学数据。
在40例已完成青春期发育的患者中,75%被诊断为努南综合征。男性青春期启动的中位年龄为11.8岁,女性为13.2岁。27.8%的患者出现青春期发育延迟,女性发病率更高。青春期启动延迟的患者最终身高的中位数显著低于发育正常的患者(p < 0.01)。接受生长激素治疗的生长激素缺乏患者与未接受治疗的患者在最终身高方面未观察到显著差异。
青春期启动延迟对RAS病患者的最终身高有负面影响,青春期追赶生长不足是常见结果。虽然大多数患者自发进入青春期,但仔细监测生长和青春期进展对于优化治疗干预和改善最终身高结局至关重要。